Angiotensin Peptide Fragments Potentiate SARS-CoV-2 Spike–AXL Receptor Interaction: Evidence, Mechanistic Insights, and Research Implications

Study Background and Research Question

The renin–angiotensin system (RAS) is a cornerstone of cardiovascular and renal physiology, tightly regulating blood pressure and fluid balance through a cascade of bioactive peptides. Among these, angiotensin II and its fragment derivatives have been extensively studied as vasoconstrictor peptide hormones in hypertension research and blood pressure regulation (internal_article). The emergence of COVID-19, caused by SARS-CoV-2, has drawn attention to the interface between cardiovascular peptide signaling and viral pathogenesis. SARS-CoV-2 utilizes its spike protein to bind host receptors, primarily ACE2, but also neuropilin-1 (NRP1) and, notably, AXL—a receptor upregulated in respiratory cells with low ACE2 expression. Whether naturally occurring angiotensin peptides modulate spike protein binding to these alternative receptors remained an open question, with significant implications for understanding tissue tropism and disease severity in COVID-19.

Key Innovation from the Reference Study

The pivotal advance in Oliveira et al. (2025) is the identification of a previously unrecognized role for angiotensin peptide fragments—including short peptides such as Angiotensin 1/2 (5-7) (H2N-Ile-His-Pro-OH)—in enhancing the binding between the SARS-CoV-2 spike protein and AXL. Using systematic truncations of angiotensin II and chemical modifications, the authors reveal that specific C- and N-terminal fragments, as well as certain amino acid substitutions, confer a marked potentiation of spike–AXL binding. This discovery positions angiotensin fragments as functional modulators at the interface of RAS peptide biology and viral entry, suggesting a molecular mechanism by which cardiovascular state may influence viral infectivity (paper).

Methods and Experimental Design Insights

The study employs antibody-based binding assays to quantitatively assess how various angiotensin peptides and their fragments affect the interaction between the SARS-CoV-2 spike protein and its receptors (ACE2, NRP1, and AXL). Key experimental features include:

• Generation of angiotensin peptide fragments via systematic N- and C-terminal deletions (including Angiotensin (1–7), (1–6), (2–8), (3–8), (2–7), and (5–7)).
• Assessment of binding enhancement using in vitro ELISA-like platforms with recombinant spike and receptor proteins.
• Site-specific substitutions and post-translational modification studies (e.g., tyrosine to valine or tyrosine phosphorylation at position 4 of angiotensin II).

By comparing the effects of these peptide variants on spike binding across all three receptors, the study discerns both sequence and modification-dependent determinants of viral–host interaction potential (paper).

Core Findings and Why They Matter

Oliveira et al. report several key findings with direct relevance for both cardiovascular and infectious disease research:

• Enhancement of Spike–AXL Binding by Angiotensin Peptides: Angiotensin II caused a two-fold increase in spike–AXL binding. Shorter fragments, including Angiotensin (1–7), (1–6), and notably N-terminal deletions (Angiotensin III (2–8), IV (3–8), (2–7), and (5–7)), showed even greater potentiation, with Angiotensin IV producing a 2.7-fold increase (paper).
• Specificity of Receptor Modulation: The enhancement effect was most pronounced for AXL, with Angiotensin IV also showing potentiation of spike binding to ACE2 and NRP1. In contrast, full-length Angiotensin I (1–10) did not affect binding.
• Role of Amino Acid Modifications: Substitution or phosphorylation of the tyrosine residue at position 4 in angiotensin II further increased spike–AXL binding, implicating specific residue chemistry in this interaction.

These results suggest that elevated levels of certain angiotensin fragments—potentially generated in disease states or through RAS modulation—may facilitate increased viral entry through non-canonical spike receptors like AXL. This effect could help explain tissue-specific susceptibility to SARS-CoV-2 and the interplay between cardiovascular status and COVID-19 outcomes (internal_article).

Comparison with Existing Internal Articles

Internal resources have previously outlined the central role of Angiotensin 1/2 (5-7) and related peptides in blood pressure regulation and cardiovascular research, highlighting its use as a vasoconstrictor peptide hormone in both mechanistic RAS studies and hypertension disease models (internal_article). However, the current reference paper extends these findings by establishing a direct link between angiotensin fragment presence and SARS-CoV-2 spike binding—specifically to the AXL receptor. This cross-domain insight was only alluded to in earlier resources, which focused primarily on cardiovascular and translational assay workflows (internal_article). The new evidence thus provides a mechanistic bridge, deepening the relevance of angiotensin peptides (including H2N-Ile-His-Pro-OH) for infectious disease modeling.

Limitations and Transferability

While the enhancement of spike–AXL binding by angiotensin peptides is robust in vitro, several limitations merit consideration:

• All experiments were conducted with recombinant proteins outside the cellular context, so the magnitude of enhancement in vivo remains to be validated.
• The physiological concentrations of angiotensin fragments required to modulate spike–AXL binding in human tissues are not yet established (paper).
• Potential feedback between RAS activity, peptide fragment production, and infection-induced inflammation in patients is not addressed in this study, limiting direct clinical extrapolation.

Nevertheless, the findings provide a strong rationale for further in vivo and translational studies examining the interplay between RAS peptide profiles, cardiovascular status, and SARS-CoV-2 susceptibility.

Why this cross-domain matters, maturity, and limitations

This study forges a mechanistic connection between the well-established field of renin-angiotensin system research and the emerging area of viral pathogenesis, specifically SARS-CoV-2 entry mechanisms. The demonstration that angiotensin peptide fragments (including Angiotensin 1/2 (5-7)) can directly enhance viral spike protein binding to AXL receptor introduces a new layer of complexity to both cardiovascular and infectious disease research. However, the evidence remains preclinical and primarily mechanistic; clinical significance and potential for therapeutic targeting will require validation in patient-derived tissues and animal models (paper).

Protocol Parameters

• binding assay (spike–AXL) | 2–2.7-fold enhancement | in vitro recombinant protein systems | Quantifies potentiation of spike binding by angiotensin fragments | paper
• peptide concentration | not specified (recommend titration: 1–100 μM) | cell-free or cellular assays | Empirical determination needed for optimal effect | workflow_recommendation
• peptide storage | -20°C (solid) | all biochemical assays | Maintains stability and reproducibility | product_spec
• solvent compatibility | ≥50 mg/mL in water, DMSO, or ethanol | preparation of peptide solutions | Ensures solubility for diverse assay setups | product_spec

Research Support Resources

To facilitate replication and further exploration of angiotensin-mediated modulation of spike–receptor interactions, researchers can utilize Angiotensin 1/2 (5-7) (SKU A1049), a rigorously characterized H2N-Ile-His-Pro-OH peptide, in receptor binding and signaling pathway assays. Its high solubility and confirmed purity support robust workflows in both cardiovascular and viral pathogenesis studies (internal_article). For detailed troubleshooting or protocol adaptation, consult recent workflow-oriented resources or reach out to APExBIO technical support.